#AACR17: Fresh from Mer­ck em­brace, fast-grow­ing In­cyte piv­ots in­to a PhI­II IDO1/Op­di­vo tie-up with Bris­tol-My­ers

PHO­TO: © AACR/Todd Buchanan 2017


Wash­ing­ton, DC — Two days af­ter In­cyte out­lined how it tied the knot with Mer­ck on a slate of six late-stage stud­ies com­bin­ing its check­point Keytru­da with the biotech’s IDO1 drug epaca­do­stat, ze­ro­ing in on front­line use, In­cyte has piv­ot­ed in­to a part­ner­ship on three stud­ies with Bris­tol-My­ers Squibb’s ri­val check­point Op­di­vo.

Like Mer­ck, Bris­tol-My­ers is look­ing for piv­otal da­ta on a front­line com­bo to tack­le non-small cell lung can­cer. And they’re adding a Phase III study that tack­les head and neck can­cer while ex­pand­ing an on­go­ing Phase I/II to in­clude an­ti-PD-1/PD-L1 re­lapsed/re­frac­to­ry co­horts of melanoma pa­tients.

Like its pact with Mer­ck, In­cyte $IN­CY is shar­ing the cost of the piv­otal work with Bris­tol-My­ers, look­ing to pen­e­trate a slate of can­cer mar­kets with lead­ers in the field. And as Mer­ck is tak­ing the lead on do­ing the re­search work on their pact, Bris­tol-My­ers is do­ing the same, In­cyte CEO Hervé Hop­penot tells me.

In­vestors loved the move in­to late-stage test­ing across a broad front, send­ing shares up 5% by late af­ter­noon on Mon­day.

Iron­i­cal­ly, In­cyte emerges from these back-to-back deals con­tin­u­ing to be close­ly al­lied with the two top play­ers in check­point in­hi­bi­tion. Mer­ck re­cent­ly seized the in­side track on non-small cell lung can­cer, leapfrog­ging a flail­ing Bris­tol-My­ers which was ham­mered — and not for the first time — as it re­cent­ly re­vealed that its com­bi­na­tion of Op­di­vo and the CT­LA-4 drug Yer­voy would not be head­ed to an ac­cel­er­at­ed re­view. And In­cyte is al­so al­ready en­gaged in pacts with As­traZeneca and Genen­tech on their check­points as well.

Hervé Hop­penot, In­cyte CEO

How about Baven­cio (avelum­ab), the new­ly ap­proved check­point from Mer­ck KGaA and Pfiz­er? I ask Hop­penot.

“We’re open to it,” he re­sponds with a ready smile.

In­cyte not on­ly has part­ner­ships with a line­up of key play­ers, it has its own check­point in de­vel­op­ment as well. (Just as Bris­tol-My­ers has its own IDO1 in ear­ly de­vel­op­ment.) The biotech is op­er­at­ing on the no­tion that epaca­do­stat has the po­ten­tial to be tied to a va­ri­ety of check­points for a list of dif­fer­ent can­cer types.

“I don’t think any­one knows how things will end up,” says Hop­penot, who views these de­vel­op­ment pacts as short term com­mit­ments. If the tri­als pan out as hoped, he says that the lead­ing IDO1 drug could be pre­scribed in com­bi­na­tions, a lu­cra­tive rev­enue source for the com­pa­ny. The deals do not in­clude com­mer­cial part­ner­ships.

In­cyte an­nounced the lat­est deal with Bris­tol-My­ers ear­ly Sun­day, as AACR was get­ting start­ed in Wash­ing­ton DC.

One of the rea­sons why IDO1 and check­points are so at­trac­tive, Hop­penot says, is that a tar­get­ed ther­a­py like an IDO1 — fo­cused on the tu­mor mi­croen­vi­ron­ment — could have a bet­ter shot at suc­cess with a check­point than, say, a PD-1 check­point and CT­LA-4 (like Yer­voy) where you’re adding a sys­temic drug that could trig­ger safe­ty is­sues for pa­tients.

The first one of these piv­otal com­bo stud­ies will be the Keytru­da/epaca­do­stat com­bo study that reads out in 2018, just around the cor­ner in R&D terms.

Leerink’s Sea­mus Fer­nan­dez en­thu­si­as­ti­cal­ly signed off on the lat­est Bris­tol-My­ers pact Mon­day morn­ing. He not­ed:

In our view, BMY’s de­ci­sion to fol­low MRK dra­mat­i­cal­ly re­duces the risk that Op­di­vo will be at risk even if the com­bi­na­tion with IDO is ul­ti­mate­ly deemed clin­i­cal­ly su­pe­ri­or to the com­bi­na­tion of CT­LA4 + PD1/PDL1. Fur­ther­more, as bio­mark­ers evolve and new treat­ment ap­proach­es evolve and emerge, it is like­ly that the PD1/PDL1 agents with the broad­est la­bels are most like­ly to ben­e­fit from this seg­men­ta­tion of the mar­ket. This “all com­ers” ap­proach to com­bi­na­tions high­lights what like­ly will con­tin­ue to be an ex­tra­or­di­nary cost of IO de­vel­op­ment and the race for lead­er­ship.

This is a crit­i­cal time for In­cyte, which is one of the biotechs most fre­quent­ly men­tioned as a like­ly takeover tar­get by over-caf­feinat­ed an­a­lysts ea­ger to pre­dict the next M&A deal. The staff of the Wilm­ing­ton, DE-based com­pa­ny has bro­ken past the 1,000 mark, with 850 in the US and the rest in Eu­rope — where In­cyte picked up the Ari­ad op­er­a­tions last May – well ahead of the Take­da buy­out in the US – for $140 mil­lion up front.

More than half of In­cyte’s staff is in R&D, with more than 200 sci­en­tists in the op­er­a­tion. And Hop­penot tells me he’s in­tent on build­ing a “flat” or­ga­ni­za­tion that is bro­ken in­to three dis­tinct re­gions: the US, Eu­rope and next in Japan.

“The ques­tion was how to be­come big with­out be­com­ing stu­pid,” says the CEO, a vet­er­an of the glob­al phar­ma gi­ant No­var­tis.

In­cyte now has 14 drugs in the clin­ic, a grow­ing top line with Jakafi sales, with rev­enue break­ing past the $1 bil­lion mark last year. These new and re­vamped pacts have helped dri­ve a big fo­cus on the pipeline.

Back in ear­ly 2015, In­cyte paid $60 mil­lion for an up­front and eq­ui­ty and promised up to $350 mil­lion in mile­stones to jump on board Agenus’s an­ti­body dis­cov­ery plat­form. That deal cov­ered a slate of check­point reg­u­la­tors that could be cru­cial to In­cyte’s fu­ture cov­er­ing GITR, OX40, LAG-3 and TIM-3. And a few weeks ago that 50/50 deal was re­jigged to leave In­cyte with the reins, with Agenus tak­ing cash and roy­al­ties in lieu of the split orig­i­nal­ly planned.

Late last year In­cyte em­braced Dutch biotech Merus and its bis­pe­cif­ic an­ti­body tech, agree­ing to buy in­to a new dis­cov­ery and de­vel­op­ment col­lab­o­ra­tion that start­ed with $200 mil­lion in an up­front and eq­ui­ty pay­ment and has the po­ten­tial to earn bil­lions more if it ma­tures in­to a co-com­mer­cial­iza­tion arrange­ment.

The key to mak­ing this all work, says Hop­penot, is to cre­ate sep­a­rate or­ga­ni­za­tions that can op­er­ate vir­tu­al­ly — though not en­tire­ly — in­de­pen­dent­ly, with­out a large hi­er­ar­chy over­see­ing every as­pect of de­vel­op­ment, slow­ing things down.

“We are a fast grow­ing com­pa­ny,” says Hop­penot. “That is not go­ing to change.”

And he isn’t about to guar­an­tee that every­thing now in the clin­ic will work.

“Some of it is go­ing to flop,” says the for­mer No­var­tis can­cer chief, who took the helm at In­cyte three-and-a-half years ago. It’s not tak­ing in­tel­li­gent, fo­cused risks that he finds a much big­ger threat. And so far, it’s all work­ing in his fa­vor.

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.

As dis­as­ter struck, Ab­b­Vie’s Rick Gon­za­lez swooped in on Al­ler­gan with an of­fer Brent Saun­ders couldn’t say no to

Early March was a no good, awful, terrible time for Allergan CEO Brent Saunders. His big lead drug had imploded in a Phase III disaster and activists were after his hide — or at least his chairman’s title — as the stock price continued a steady droop that had eviscerated share value for investors.

But it was a perfect time for AbbVie CEO Rick Gonzalez to pick up the phone and ask Saunders if he’d like to consider a “strategic” deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

CEO Pascal Soriot via Getty Images

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.

Wednesday morning the pharma giant and their partners at Merck parted the curtains on a successful readout for their Phase III PAOLA-1 study, demonstrating statistically significant improvement in progression-free survival for women with ovarian cancer in a first-line maintenance setting who added their PARP Lynparza to Avastin. This is their second late-stage success in ovarian cancer, which will help stave off rivals like GSK.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.